Health and Medicine
FDA Approves Merck's Lipfendra, First Oral Cholesterol Pill
FDA approves Merck's Lipfendra (enlicitide), the first oral PCSK9 inhibitor that lowers LDL cholesterol by up to 59%, far surpassing statins.
—5 min read
Category
1 article
FDA approves Merck's Lipfendra (enlicitide), the first oral PCSK9 inhibitor that lowers LDL cholesterol by up to 59%, far surpassing statins.